Vyepti study misfire makes for learning experience for Lundbeck
Although it was on the smaller scale, a Vyepti study in China still did not produce the confidence-inspiring data Lundbeck had hoped for. ”We have learned a lot,” says CEO Deborah Dunsire.
by marketwire, translated by daniel pedersen
Lundbeck met some resistance in the rollout of key product Vyepti, a preventive migraine treatment, when a smaller study in China did not deliver convincing results.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Key products generate strong Q2 result for Lundbeck
For subscribers
Lundbeck raises 2022 guidance
For subscribers
